PDCD1 and glioblastoma: The frequent use of glucocorticoids, the insufficient intratumoral bio-distribution of therapeutic antibodies (such as anti-PD-1 and anti-PD-L1), and the induction of peripheral immunity are additional factors that restrict the efficacy of immunotherapy in treating GBM.